Article Text

Download PDFPDF

Late breaking news symposium

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


1N. M. Rahman, 2N. Maskell, 3C. W. H. Davies, 4A. West, 5R. Teoh, 5A. Arnold, 6D. Peckham, 7N. Ali, 8A. Bentley, 9C. I. Mackinlay, 10W. J. Kinnear, 1J. M. Wrightson, 1H. E. Davies, 11R. F. Miller, 12Y. C. G. Lee, 1E. L. Hedley, 1N. Crosthwaite, 13L. Choo, 13J. Darbyshire, 1F. V. Gleeson, 13A. J. Nunn, 1R. J. O. Davies. 1Oxford Centre for Respiratory Medicine, Oxford, UK, 2Southmead Hospital, Bristol, UK, 3Royal Berkshire Hospital, Reading, UK, 4Medway Maritime Hospital, Gillingham, UK, 5Castle Hill Hospital, Cottingham, UK, 6St James Hospital, Leeds, UK, 7Kingsmill Hospital, Mansfield, UK, 8Wythenshawe Hospital, Manchester, UK, 9Great Western Hospital, Swindon, UK, 10Queen’s Medical Centre, Nottingham, UK, 11University College London, London, UK, 12University of Western Australia, Perth, Australia, 13MRC Clinical Trials Unit, London, UK

Background Pleural infection affects >65 000 patients per annum (UK + USA). 35% of these patients die or require surgery. Previous evidence suggests no benefit from intrapleural fibrinolytic agents although this is still debated. Direct plasminogen activators (tissue plasminogen activator (tPA)) and DNase to disrupt pleural biofilms and decrease pus viscosity may improve outcomes alone or in combination, but have not been tested in randomised trials.

Methods The Second Multicentre Intrapleural Sepsis (MIST2) trial is a double-blind, placebo-controlled 2×2 factorial trial of intrapleural tPA and DNase. 210 patients with microbiology-positive pleural fluid, or pH <7.2 or purulent pleural fluid in the correct clinical context, from 11 centres were randomised to: double-matched placebo, active tPA plus active DNase, active tPA plus placebo DNase, or placebo tPA plus active DNase for 3 days (tPA 10 mg bd, DNase 5 mg bd). The primary outcome was change in chest radiograph effusion opacity from day 1 to day 7 postrandomisation. Group unblinded data only are presented here.

Results Participants were 58.8 (SD 17.8) years, 60% male; 173/199 (87%) had community-acquired infection. Baseline characteristics were balanced across the treatment arms. Combination tPA/DNase was significantly superior to the other interventions. There was no evidence of improved drainage with tPA or DNase alone (absolute reduction in size of effusion as a percentage of hemithorax, tPA/DNase 29.7% SD 23.1; placebo/placebo 17.1% SD 24.1; tPA/placebo 15.1% SD 17.4; DNase/placebo 17.1% SD 19.6; test for interaction p = 0.002, 95% CI 5.0% to 22.9%). The proportion of patients dying or requiring surgery for their infection was higher in the DNase/placebo group and similar in all other groups (number of deaths or surgery, tPA/DNase 9/52 (17.3%); placebo/placebo 7/55 (12.7%); tPA/placebo 8/52 (15.4%), DNase/placebo 23/51 (45.1%), χ2 3 df = 20.3, p = 0.0001). The occurrence of serious haemorrhage was not different between the groups (4 cases overall).

Conclusion Combination intrapleural tPA/DNase substantially improves pleural fluid drainage in pleural infection. DNase or tPA alone are ineffective and DNase alone appears to be associated with an increased frequency of surgery/death. The frequency of haemorrhage is not increased by these treatments.

View Abstract